Memphasys Expands Felix Commercial Footprint in Japan
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Memphasys Ltd has announced a repeat order for Felix cartridges from the Nishitan ART Clinic Group in Japan, indicating growing traction for its technology in IVF workflows. Memphasys aims to leverage this relationship to enhance its presence in the self-pay IVF segment, which is increasingly seeking innovative solutions. The company plans to support clinics through product demonstrations and training, with expectations of continued momentum in the Japanese market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- Response to ASX Aware Letter
- Non-Renounceable Issue
- LR4.3D - adjustment to financial statements
- Investor Presentation - commercialisation of FELIX
- Placement Accelerates Felix Commercialisation and Manufactur
Later from Memphasys
- MEM Secures Indian Supply Deal Under Go-Direct Strategy
- Completion of Entitlement Offer
- Felix Middle East Direct Sales Strategy
- Memphasys Implements Leadership Restructure
- Key MENA Partner Secures Early Felix Cartridge Order
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys